[go: up one dir, main page]

MX2019007411A - Reuso de enzimas en glucomanipulacion in vitro de anticuerpos. - Google Patents

Reuso de enzimas en glucomanipulacion in vitro de anticuerpos.

Info

Publication number
MX2019007411A
MX2019007411A MX2019007411A MX2019007411A MX2019007411A MX 2019007411 A MX2019007411 A MX 2019007411A MX 2019007411 A MX2019007411 A MX 2019007411A MX 2019007411 A MX2019007411 A MX 2019007411A MX 2019007411 A MX2019007411 A MX 2019007411A
Authority
MX
Mexico
Prior art keywords
enzymes
region
antibody
glycosylation
antibodies
Prior art date
Application number
MX2019007411A
Other languages
English (en)
Inventor
Falkenstein Roberto
Walch Heiko
Malik Sebastian
Thomann Marco
Grunert Ingrid
Freiherr Von Roman Matthias
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2019007411A publication Critical patent/MX2019007411A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction, e.g. ion-exchange, ion-pair, ion-suppression or ion-exclusion
    • B01D15/361—Ion-exchange
    • B01D15/362—Cation-exchange
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)

Abstract

En la presente descripción se informa de un método para la preparación/producción enzimática de un anticuerpo con una glucosilación modificada en la región Fc que comprende las etapas de incubar un anticuerpo que presenta una glucosilación en la región Fc con uno o más enzimas durante un tiempo suficiente y bajo condiciones adecuadas para modificar la glucosilación de la región Fc hasta una forma definida, separar en una o más etapas cromatográficas el anticuerpo con una glucosilación modificada en la región Fc respecto del enzima o enzimas y producir de esta manera el anticuerpo con una glucosilación modificada en la región Fc y uno o más enzimas reciclados y repetir la etapa de incubación con uno o más enzimas reciclados por lo menos una vez.
MX2019007411A 2016-12-21 2017-12-19 Reuso de enzimas en glucomanipulacion in vitro de anticuerpos. MX2019007411A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16205586 2016-12-21
EP17157005 2017-02-20
PCT/EP2017/083430 WO2018114878A1 (en) 2016-12-21 2017-12-19 Re-use of enzymes in in vitro glycoengineering of antibodies

Publications (1)

Publication Number Publication Date
MX2019007411A true MX2019007411A (es) 2019-08-29

Family

ID=61094375

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019007411A MX2019007411A (es) 2016-12-21 2017-12-19 Reuso de enzimas en glucomanipulacion in vitro de anticuerpos.

Country Status (11)

Country Link
US (1) US12269867B2 (es)
EP (1) EP3559250A1 (es)
JP (1) JP6931058B2 (es)
KR (1) KR102390246B1 (es)
CN (1) CN110100007B (es)
AU (1) AU2017381656B2 (es)
CA (1) CA3043158A1 (es)
IL (1) IL267349A (es)
MX (1) MX2019007411A (es)
TW (1) TWI778000B (es)
WO (1) WO2018114878A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202012993SA (en) 2018-07-13 2021-02-25 Genmab As Variants of cd38 antibody and uses thereof
MA53123A (fr) 2018-07-13 2021-05-19 Genmab As Thérapie à médiation par trogocytose utilisant des anticorps cd38
CA3115821A1 (en) * 2018-10-11 2020-04-16 Momenta Pharmaceuticals, Inc. Treatment with highly silylated igg compositions
BR112022013553A2 (pt) 2020-01-16 2022-09-06 Genmab As Composição farmacêutica, anticorpo, e, método para tratar uma doença
MX2022010826A (es) * 2020-03-05 2022-12-02 Momenta Pharmaceuticals Inc Métodos para elaborar inmunoglobulina hipersialilada.
KR20230012576A (ko) * 2020-05-19 2023-01-26 모멘타 파머슈티컬스 인코포레이티드 하이퍼-시알릴화 면역글로불린
WO2023031473A1 (en) 2021-09-06 2023-03-09 Genmab B.V. Antibodies capable of binding to cd27, variants thereof and uses thereof
WO2024235862A1 (en) 2023-05-12 2024-11-21 Genmab A/S Antibodies capable of binding to ox40, variants thereof and uses thereof

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
US5202238A (en) 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
CA2405246A1 (en) 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with alterred binding properties
JP3476455B2 (ja) 1991-03-18 2003-12-10 ザ スクリップス リサーチ インスティテュート ＮｅｕＡｃα２、６Ｇａｌβ１、４ＧｌｃＮＡｃ及びシアリルＬｅｘの合成法
DE122004000008I1 (de) 1991-06-14 2005-06-09 Genentech Inc Humanisierter Heregulin Antikörper.
EP0604580A1 (en) 1991-09-19 1994-07-06 Genentech, Inc. EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab') 2? ANTIBODIES
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
WO1998033523A1 (en) 1997-01-31 1998-08-06 Biovation Limited Vaccination methods and molecules
DE69833755T2 (de) 1997-05-21 2006-12-28 Biovation Ltd. Verfahren zur herstellung von nicht-immunogenen proteinen
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
US6610833B1 (en) 1997-11-24 2003-08-26 The Institute For Human Genetics And Biochemistry Monoclonal human natural antibodies
WO1999029888A1 (en) 1997-12-05 1999-06-17 The Scripps Research Institute Humanization of murine antibody
EP1051432B1 (en) 1998-12-08 2007-01-24 Biovation Limited Method for reducing immunogenicity of proteins
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
ATE303445T1 (de) 1999-10-04 2005-09-15 Medicago Inc Verfahren zur regulation der transkription von fremden genen in gegenwart von stickstoff
AU784983B2 (en) 1999-12-15 2006-08-17 Genentech Inc. Shotgun scanning, a combinatorial method for mapping functional protein epitopes
MXPA02010011A (es) 2000-04-11 2003-04-25 Genentech Inc Anticuerpos multivalentes y usos para los mismos.
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
IL155977A0 (en) 2000-11-30 2003-12-23 Medarex Inc Transgenic transchromosomal rodents for making human antibodies
NZ556507A (en) 2002-06-03 2010-03-26 Genentech Inc Synthetic antibody phage libraries
WO2004065416A2 (en) 2003-01-16 2004-08-05 Genentech, Inc. Synthetic antibody phage libraries
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
EP1460425A1 (en) 2003-03-17 2004-09-22 Boehringer Mannheim Gmbh Deglycosylated enzymes for conjugates
ES2313079T3 (es) 2003-07-28 2009-03-01 Janssen Pharmaceutica Nv Benzimidazol, benzotiazol, benzoxazol y su utilizacion como moduladores de lta4h.
WO2005097832A2 (en) 2004-03-31 2005-10-20 Genentech, Inc. Humanized anti-tgf-beta antibodies
US7785903B2 (en) 2004-04-09 2010-08-31 Genentech, Inc. Variable domain library and uses
WO2005111627A2 (en) 2004-04-15 2005-11-24 Massachusetts Institute Of Technology Methods and products related to the improved analysis of carbohydrates
US20060127950A1 (en) 2004-04-15 2006-06-15 Massachusetts Institute Of Technology Methods and products related to the improved analysis of carbohydrates
TWI380996B (zh) 2004-09-17 2013-01-01 Hoffmann La Roche 抗ｏｘ４０ｌ抗體
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
AU2006265676B2 (en) * 2005-06-30 2013-01-24 Centocor, Inc. Methods and compositions with enhanced therapeutic activity
EP2465870A1 (en) 2005-11-07 2012-06-20 Genentech, Inc. Binding polypeptides with diversified and consensus VH/VL hypervariable sequences
US20070237764A1 (en) 2005-12-02 2007-10-11 Genentech, Inc. Binding polypeptides with restricted diversity sequences
AU2007249408A1 (en) 2006-05-09 2007-11-22 Genentech, Inc. Binding polypeptides with optimized scaffolds
US20070266448A1 (en) 2006-05-11 2007-11-15 Alexander Lifke Method for the production of antibodies
US20080242607A1 (en) 2006-07-21 2008-10-02 Neose Technologies, Inc. Glycosylation of peptides via o-linked glycosylation sequences
WO2008027236A2 (en) 2006-08-30 2008-03-06 Genentech, Inc. Multispecific antibodies
CN100592373C (zh) 2007-05-25 2010-02-24 群康科技(深圳)有限公司 液晶显示面板驱动装置及其驱动方法
JP2010536355A (ja) 2007-08-31 2010-12-02 エフ．ホフマン−ラ ロシュ アーゲー グリコシル化プロファイル分析
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
US8227577B2 (en) 2007-12-21 2012-07-24 Hoffman-La Roche Inc. Bivalent, bispecific antibodies
US8242247B2 (en) 2007-12-21 2012-08-14 Hoffmann-La Roche Inc. Bivalent, bispecific antibodies
WO2009089004A1 (en) 2008-01-07 2009-07-16 Amgen Inc. Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
WO2009089396A2 (en) * 2008-01-08 2009-07-16 Neose Technologies, Inc. Glycoconjugation of polypeptides using oligosaccharyltransferases
BRPI1014089A2 (pt) 2009-04-02 2016-04-19 Roche Glycart Ag anticorpos multiespecíficos que compreendem anticorpos de comprimento completo e fragmentos fab de cadeia simples
PT2417156E (pt) 2009-04-07 2015-04-29 Roche Glycart Ag Anticorpos trivalentes, biespecíficos
WO2010136172A1 (en) 2009-05-27 2010-12-02 F. Hoffmann-La Roche Ag Tri- or tetraspecific antibodies
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
US8703132B2 (en) 2009-06-18 2014-04-22 Hoffmann-La Roche, Inc. Bispecific, tetravalent antigen binding proteins
US8524470B2 (en) * 2009-07-30 2013-09-03 Hoffman-La Roche, Inc. Enzymatic antibody processing
US10087236B2 (en) 2009-12-02 2018-10-02 Academia Sinica Methods for modifying human antibodies by glycan engineering
ES2534936T3 (es) * 2010-08-02 2015-04-30 Ratiopharm Gmbh Método para producir y purificar una sialiltransferasa soluble activa
ES2767135T3 (es) 2011-10-19 2020-06-16 Novimmune Sa Métodos para purificar anticuerpos
BR112014019825B1 (pt) 2012-02-10 2021-08-24 University Of Maryland, Baltimore Glicoengenharia quimioenzimática de anticorpos e fragmentos fc dos mesmos
US9150645B2 (en) 2012-04-20 2015-10-06 Abbvie, Inc. Cell culture methods to reduce acidic species
EP3108004B1 (en) * 2014-02-18 2019-02-20 The University of Manitoba Methods to produce single glycoform antibodies
EP3567056A1 (en) * 2014-09-10 2019-11-13 F. Hoffmann-La Roche AG Galactoengineered immunoglobulin 1 antibodies
MY193014A (en) 2015-10-27 2022-09-22 Hoffmann La Roche Peptide macrocycles against acinetobacter baumannii
AU2017384276B9 (en) 2016-12-21 2020-11-26 F. Hoffmann-La Roche Ag In vitro glycoengineering of antibodies

Also Published As

Publication number Publication date
CN110100007A (zh) 2019-08-06
IL267349A (en) 2019-08-29
TWI778000B (zh) 2022-09-21
KR20190084313A (ko) 2019-07-16
CN110100007B (zh) 2024-05-28
KR102390246B1 (ko) 2022-04-22
US12269867B2 (en) 2025-04-08
BR112019009839A2 (pt) 2019-09-17
AU2017381656B2 (en) 2020-07-02
JP6931058B2 (ja) 2021-09-01
TW201835332A (zh) 2018-10-01
AU2017381656A1 (en) 2019-05-23
EP3559250A1 (en) 2019-10-30
CA3043158A1 (en) 2018-06-28
WO2018114878A1 (en) 2018-06-28
US20200165321A1 (en) 2020-05-28
JP2020501576A (ja) 2020-01-23

Similar Documents

Publication Publication Date Title
MX2019007411A (es) Reuso de enzimas en glucomanipulacion in vitro de anticuerpos.
MX2019006266A (es) Glucomanipulacion in vitro de anticuerpos.
MX2019006123A (es) Metodo para glicomanipulacion in vitro de anticuerpos.
MX2019007782A (es) Una variante de isopropilmalato sintasa novedosa y un procedimiento de producción de l-leucina usando la misma.
CL2019002793A1 (es) Composición para producir tagatosa y procedimiento de producción de tagatosa usando la misma.
AR085302A1 (es) Metodo de produccion de anticuerpos sialilados
WO2016171224A9 (ja) タンパク質の分泌生産法
MX2019009414A (es) Conformado con doble diafragma de materiales compuestos, ensamblajes para el conformado y materiales compuestos resultantes.
BR112016009365A2 (pt) Método para aumentar, melhorar e estender a produção de etanol e método para diminuir as concentrações finais de dp2 em um produto de fermentação
MY172080A (en) Microorganisms having putrescine productivity and process for producing putrescine using the same
PH12020500115A1 (en) cAMP RECEPTOR PROTEIN VARIANT AND METHOD OF PRODUCING L-AMINO ACID USING THE SAME
MX2018004580A (es) Metodo para producir proteina de fusion con dominio fc de igg.
CR20200564A (es) Anticuerpos anti-tmeff2 monoespecificos y multiespecificos y sus usos
PH12020550976A1 (en) Camp receptor protein variant and method of producing l-amino acid using the same
PH12019500096A1 (en) Leuconostoc mesenteroides cjlm119 strain producing reduced amount of gas, and kimchi production method using same
MX2019015868A (es) Nueva psicosa-6-fosfato fosfatasa, composición para producir psicosa que incluye dicha enzima, método para producir psicosa usando dicha enzima.
ZA202205485B (en) L-methionine producing microorganism to which protein encoded by foreign metz gene is introduced and method for producing l-methionine using same
UY37398A (es) Proceso para la producción de un ácido orgánico a partir de un material de partida lignocelulósico
SG11201806843UA (en) Method for producing activated hepatocyte growth factor (hgf)
PH12022550820A1 (en) Yeast strain producing glutathione and method of producing glutathione using the same
MX2015003596A (es) Plantilla de montaje de anillo, procedimiento de montaje de un anillo, y procedimiento de produccion de un arbol.
MY195698A (en) Fermented Soybean Composition and Method for Producing Fermented Soybean Composition
MX366688B (es) Método y composición para mejorar la productividad de plantas no leguminosas.
MX2024008725A (es) Material aerosolizable.
PH12021550013A1 (en) Method for producing protein